BofA Securities Reiterates Buy Rating on Ionis Pharmaceuticals (IONS) Following Weak Competitor Data
Tweet Send to a Friend
BofA Securities analyst Jason Gerberry reiterated a Buy rating and $70.00 price target on Ionis Pharmaceuticals (NASDAQ: IONS) after data ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
